Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Altinicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 6/20 | 0.79 |
| ▸ | CHRNA4 known ✓ | P43681 | 5/20 | 0.79 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.79 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.79 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.79 |
| ▸ | CHRNA2 | Q15822 | 3/20 | 0.79 |
| ▸ | CHRNG | P07510 | 2/20 | 0.79 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.79 |
| ▸ | CHRND | Q07001 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Altinicline SCHEMBL15253516 | 1.00 | CHRNA3 (0.79) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Altinicline SCHEMBL3099334 | 1.00 | CHRNA3 (0.79) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Altinicline SCHEMBL3099328 | 1.00 | CHRNA3 (0.79) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Altinicline SCHEMBL1155706 | 0.89 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Altinicline SCHEMBL1155703 | 0.89 | CHRNA3 (1.00) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Fumaric Acid SCHEMBL6961573 | 0.87 | CHRNB4 (0.59) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Fumaric Acid SCHEMBL6960621 | 0.85 | CHRNB4 (0.57) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Fumaric Acid SCHEMBL6960624 | 0.85 | CHRNB4 (0.57) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Fumaric Acid SCHEMBL6972261 | 0.83 | CHRNA3 (0.54) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 | |
| Fumaric Acid SCHEMBL6961456 | 0.82 | CHRNB4 (0.53) | CHRNA3CHRNB2CHRNB4CHRNA4CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | RESILIO COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| EP-2559693-B1 | Polycyclic compound | EISAI R&D MAN CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| CN-102333777-B | Nitrogen-containing fused heterocyclic compounds and their use as beta-amyloid production inhibitors | EISAI R&D MAN CO LTD | 2014-06-25 | — | — | CN | disclosed |
| US-8754100-B2 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| CN-101815713-B | Polycyclic compounds | EISAI R&D MAN CO LTD | 2013-09-11 | — | — | CN | disclosed |
| EP-2615090-A1 | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2013-07-17 | — | — | EP | disclosed |
| EP-2401276-B1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS BETA AMYLOID PRODUCTION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| EP-0739342-B1 | PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS | MERCK & CO INC (US) | 2003-08-27 | — | — | EP | disclosed |
| US-5723477-A | CENTRAL NERVOUS SYSTEM OR AUTONOMIC NERVOUS SYSTEM, CARDIOVASCULAR DISORDERS, GASTROINTESTINAL DISORDERS OR DRUG ABUSE | SIBIA NEUROSCIENCES, INC. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5705512-A | COGNITION ACTIVATORS USING PYRROLIDINE PYRIDINE | SIBIA NEUROSCIENCES, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5703100-A | PSYCHOLOGICAL DISORDERS; COGNITION ACTIVATORS; GASTROINTESTINAL DISORDERS; CARDIOVASCULAR DISORDERS | SIBIA NEUROSCIENCES, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5677459-A | PYRIDINE COMPOUNDS | SIBIA NEUROSCIENCES, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5594011-A | Modulators of acetylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0739342-A1 | PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| WO-1996015123-A1 | PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | CHRNB2 141/4885CHRNA4 361/4885CHRNA3 441/4885 |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | BDNF, BACE1, GAP43 | CHRNB2 47/4885CHRNA4 109/4885CHRNA3 32/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | CHRNB2 209/4885CHRNA4 521/4885CHRNA3 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.